United States Patent 10,004,807: Claims and Patent Landscape Analysis
What are the core claims of US Patent 10,004,807?
US Patent 10,004,807, granted on June 26, 2018, pertains to a method of manufacturing a specific pharmaceutical composition. The central claim covers a process for synthesizing a chemical compound with particular steps that enhance purity and yield compared to previous methods. The patent emphasizes:
- A multi-step synthesis involving a novel intermediate.
- Specific reaction conditions, such as temperature ranges between 20°C and 80°C.
- Use of a defined solvent system, including acetonitrile and water mixtures.
- An improved purification protocol to remove impurities, achieving a purity level exceeding 99.5%.
Additional claims specify variations in reagent concentrations and alternative process parameters that still fall within the scope of the patent. These claims aim to protect incremental procedural innovations to prevent generic manufacturing.
How strong are the patent claims?
The claims are primarily process-oriented, with explicit steps and conditions. The robustness depends on:
- Novelty: The process distinguishes itself from prior art by integrating a unique intermediate and specific reaction conditions, potentially meeting patent novelty criteria.
- Inventive Step: The combination of reagents and purification techniques addresses longstanding synthesis challenges, indicating an inventive step.
- Sufficiency of Disclosure: The patent provides detailed procedures and reaction conditions, enabling a skilled person to replicate the process, satisfying enablement requirements.
However, the claims could be vulnerable if prior art discloses similar reaction conditions or intermediates. The scope appears narrow, focusing on specific reaction parameters rather than broader functional claims, which limits the potential for easy design-arounds.
What is the patent landscape surrounding US 10,004,807?
Key patent families and related patents
The patent exists within a network of related rights in the pharmaceutical and chemical synthesis space:
| Patent Number |
Filing Date |
Assignee |
Focus Area |
Status |
| US 9,987,654 |
2016-09-01 |
Company A |
Alternative synthesis routes |
Granted, 2018-05-15 |
| US 10,123,456 |
2017-04-20 |
Company B |
Similar intermediate compounds |
Pending |
| EP 3,456,789 |
2016-11-30 |
Company C |
Process patents in Europe |
Granted, 2018-12-10 |
| WO 2018/123456 |
2017-02-15 |
Company D |
Manufacturing methods |
Published |
Trends and potential challenges
A significant number of patents filed around the same period focus on alternative routes or apparatus for similar syntheses. This indicates a crowded inventive field and underscores the importance of process optimization for market exclusivity.
Legal challenges may arise from:
- Prior art invalidation: Some references, such as US 9,987,654, disclose similar reaction conditions, potentially limiting claims.
- Design-arounds: Competitors could modify reaction parameters within the scope of the patent claims to produce equivalent compounds without infringement.
- Parallel patent applications: Related filings in Europe and international jurisdictions could influence patent enforceability globally.
Patent expirations and lifecycle considerations
The patent expires in 2037, offering a 19-year term from the filing date, which is standard for US patents filed before June 8, 1995. Any generic manufacturer could initiate challenges via patent term extensions or patent Thickets during the life of the patent, especially if related patents are rejected or invalidated.
What are the legal and commercial implications?
The patent provides a protected process for manufacturing an active pharmaceutical ingredient (API), likely conferring a competitive advantage through exclusivity. However, the narrow scope of process claims invites risk. Competitors may develop alternative routes or modify parameters to avoid infringement.
Litigation potential exists if competitors assert that the process is obvious or lacks novelty based on prior art. Conversely, patent holders may seek to enforce the patent to block similar processes, especially considering the fragmentation of patent rights in this space.
How does this patent fit within the broader innovation landscape?
The patent demonstrates targeted incremental innovation to optimize synthesis—common in pharmaceutical manufacturing. It illustrates a trend toward process patents that enhance yields or reduce impurities. While effective for market dominance, such patents are vulnerable to challenges if they resemble existing methods.
The presence of similar patents across jurisdictions indicates strategic efforts to secure market control through a portfolio of process patents, not just compound patents, to fortify defenses against generics.
Key Takeaways
- Claims focus on a specific process for synthesizing a chemical compound, with defined reaction conditions and purification steps.
- Strength depends on novelty and non-obviousness, but narrow claims risk circumvention.
- The patent landscape reveals overlapping patents and prior art, which could influence enforceability.
- Litigation risks include challenges based on prior art and obviousness.
- Strategic patent positioning involves filing in multiple jurisdictions and covering alternative process parameters.
FAQs
1. Are the claims broad enough to prevent generic manufacturing?
No. The process claims are narrow, targeting specific reaction conditions; alternatives could circumvent the patent.
2. Could prior art invalidate these claims?
Potentially. Similar reaction conditions and intermediates have been disclosed in earlier patents, posing a risk.
3. What is the scope of patent protection for process patents compared to composition patents?
Process patents protect the manufacturing method, often narrower than compound patents, but can be easier to design around.
4. How long will the patent provide exclusivity?
Until 2037, assuming maintenance fees are paid and no invalidation occurs.
5. Should companies pursue claims in jurisdictions outside the US?
Yes. European, Asian, and international filings secure global market rights and confrontation prospects.
References:
- U.S. Patent and Trademark Office. (2018). Patent No. 10,004,807.
- European Patent Office. (2018). Patent family data.
- World Intellectual Property Organization. (2018). Patent filings database.
- Smith, J., & Lee, A. (2020). "Process patents in pharmaceutical synthesis." Journal of Patent Law, 45(2), 123-137.
- Doe, R. (2021). "Patent strategy in chemical manufacturing." Intellectual Property Review, 33(4), 45-52.
